MedTrace Logo

Drug Interaction Study of Warfarin and MT-3995

NCT02531568 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-10-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of MT-3995 on the PK of warfarin

Conditions

  • Healthy

Interventions

DRUG

Warfarin

DRUG

MT-3995

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Horst Heuer, Dr · Nuvisan GmbH

Study Design

Purpose
SCREENING
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-08-31
Completion
2015-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02531568 on ClinicalTrials.gov